RaymondLeonWoosleyJr.MDPhD

PubMed

• 1 citations
  Linking Technology to Address the Social and Medical Determinants of Health for Safe Medicines Use.
  Raymond L. Woosley, June Simmons, Ester M. Sefilyan, Sandy Atkins, Kristin Black, William A. Read> ;Journal of Patient Safety. 2021 Jun 5
• 3 citations
  Assisted prescribing: Clinical decision support with MedSafety Scan now available.
  Raymond L. Woosley> ;Trends in Cardiovascular Medicine. 2020 Nov 10
• 1 citations
  Investigating the Impact of Gadolinium-Based Contrast Agents on the Corrected QT Interval.
  Kyle Gress, Tyler Gallo, Ivan Urits, Xue Geng, Omar Viswanath, Alan D. Kaye, Raymond L. Woosley> ;Cureus. 2020 Aug 11
• 11 citations
  Identification of populations likely to benefit from pharmacogenomic testing.
  Craig William Heise, Tyler Gallo, Steven C. Curry, Raymond L. Woosley> ;Pharmacogenetics and Genomics. 2020 Mar 23
• 5 citations
  When prescribing drugs, do medical doctors and healthcare professionals realize that their patient has the long QT syndrome?
  Peter J. Schwartz, Raymond L. Woosley, Lia Crotti> ;European Heart Journal. 2019 Oct 1
• 12 citations
  Arrhythmogenic foods - A growing medical problem.
  Raymond L. Woosley> ;Trends in Cardiovascular Medicine. 2020 Jul 1
• 3 citations
  Summary of Torsades de Pointes (TdP) Reports Associated with Intravenous Drug Formulations Containing the Preservative Chlorobutanol
  R. David Woosley, Klaus Romero, Craig William Heise, Tyler Gallo, Jared Tate, Raymond L. Woosley> ;Drug Safety. 2019 Jul 1
• 6 citations
  A computerized scoring system to improve assessment of heparin-induced thrombocytopenia risk
  Tyler Gallo, Steven C. Curry, Angela Padilla-Jones, Craig William Heise, K S Ramos, Raymond L. Woosley, Robert Raschke> ;Journal of Thrombosis and Haemostasis. 2019 Feb 1
• Farewell to Our Good Friend, Outstanding Mentor, and Colleague Darrell R. Abernethy (1949-2017).
  Janice B. Schwartz, Raymond L. Woosley, Carl C. Peck> ;Clinical Pharmacology and Therapeutics. 2018 Apr 1
• 62 citations
  CredibleMeds.org: What does it offer?
  Raymond L. Woosley, Kristin Black, C. William Heise, Klaus Romero> ;Trends in Cardiovascular Medicine. 2018 Feb 1
• 1 citations
  Counterfeit drugs: A plot worthy of John le Carrè.
  Raymond L. Woosley, Peter J. Schwartz> ;International Journal of Cardiology. 2017 Sep 15
• 75 citations
  Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.
  David G. Strauss, Jose Vicente, Lars Johannesen, Ksenia Blinova, Jay W. Mason, Peter Weeke, Elijah R. Behr, Dan M. Roden, Raymond L. Woosley, Gulum Kosova, Michael A. ...> ;Circulation. 2017 Apr 4
• 31 citations
  Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death.
  Raymond L. Woosley, Klaus Romero, Craig William Heise, Tyler Gallo, Jared Tate, Raymond David Woosley, Sophie Ward> ;Drug Safety. 2017 Mar 8
• 42 citations
  Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation.
  Tal Lorberbaum, Kevin J. Sampson, Jeremy B. Chang, Vivek Iyer, Raymond L. Woosley, Robert S. Kass, Nicholas P. Tatonetti> ;Journal of the American College of Cardiology. 2016 Oct 18
• 189 citations
  Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.
  Peter J. Schwartz, Raymond L. Woosley> ;Journal of the American College of Cardiology. 2016 Apr 5
• 23 citations
  An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval
  Tal Lorberbaum, Kevin J. Sampson, Raymond L. Woosley, Robert S. Kass, Nicholas P. Tatonetti> ;Drug Safety. 2016 Feb 10
• 1 citations
  Farewell to our Good Friend and Outstanding Colleague David Flockhart (1952-2015).
  Carl C. Peck, Raymond L. Woosley> ;Clinical Pharmacology and Therapeutics. 2016 Feb 1
• 12 citations
  Medical decision support systems and therapeutics: The role of autopilots
  Raymond L. Woosley, John Whyte, Ali Mohamadi, Klaus Romero> ;Clinical Pharmacology and Therapeutics. 2016 Feb 1
• 9 citations
  Investigation of potential mechanisms of sex differences in quinidine-induced torsade de pointes risk
  Jose Vicente, Jacob Simlund, Lars Johannesen, Frida Sundh, Jeffry Florian, Martin Ugander, Galen S. Wagner, Raymond L. Woosley, David G. Strauss> ;Journal of Electrocardiology. 2015 Jul 1
• An interview with Raymond L. Woosley.
  Raymond L Woosley> ;Trends in Pharmacological Sciences. 2014 Jun 6
• 3 citations
  Evolving Global Regulatory Science Through the Voluntary Submission of Data: A 2013 Assessment
  Elizabeth G. Walker, Martha Brumfield, Carolyn C. Compton, Raymond Woosley> ;Therapeutic Innovation & Regulatory Science. 2014 Mar 1
• 52 citations
  Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics
  Pieter G. Postema, Jon Neville, Jonas S.S.G. de Jong, Klaus Romero, Arthur A.M. Wilde, Raymond L. Woosley> ;Europace. 2013 Jul 1
• 28 citations
  Assessing cardiovascular drug safety for clinical decision-making
  Raymond L. Woosley, Klaus Romero> ;Nature Reviews. Cardiology. 2013 Jun 1
• It is important research, but why is it necessary?
  Raymond L. Woosley> ;Clinical Pharmacology and Therapeutics. 2013 Apr 1
• 5 citations
  Regulatory and Reimbursement Innovation
  Rachel A. Lindor, Scott J. Allocco, Lee Cheatham, Denis A. Cortese, Ralph F. Hall, William J. Mangold, Vincent B. Pizziconi, George Poste, Bruce Quinn, Mollie Roth, Mi...> ;Science Translational Medicine. 2013 Mar 13
• Join now to see all

Journal Articles

• Smartphone app offers online access to QT-prolonging drugs database  
  Woosley R, Cardiology Today, 1/4/2017
• Website publishes risk categories for QT-Prolonging Drugs  
  Woosley R, Cardiology Today, 1/1/2017
• Predicting the Unpredictable: Drug-induced QT prolongation and torsades de pointes  
  Schwartz P and Woosley RL, J Amer Coll Card, 1/1/2016
• An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval  
  Lorberbaum T, Sampson KJ, Woosley RL, Kass RS, Tatonetti NP, Drug Safety, 1/1/2016
• Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation  
  Lorberbaum T, Sampson KJ, Chang JB, Iyer V, Woosley RL, Kass RS et al, J Am Coll Cardiol, 1/1/2016
• Medical Decision Support Systems and Therapeutics - The Role of Auto-Pilots  
  Woosley RL, Whyte J, Mohamadi A, Romero K, Clin Pharmacol Ther, 1/1/2015
• Investigation of potential mechanisms of sex differences in quinidine-induced torsade de pointes risk  
  Vicente J, Simlund J, Johannesen L, Sundh F, Florian J, Ugander M, Wagner GS, Woosley RL, Strauss DG, J Electrocardiol, 1/1/2015
• Use of drugs in Long QT Syndrome Type 3 and Brugada Syndrome, Cardiac Sodium Channel Disorders  
  Postema PG and Woosley RL, Cardiology Electrophysiology Clinics, 1/1/2014
• Evolving Global Regulatory Science Through the Voluntary Submission of Data: A 2013 Assessment  
  Walker EG, Brumfield M, Compton C and Woosley R, Therapeutic Innovation & Regulatory Science, 1/29/2013
• One hundred years of drug regulation: where do we go from here?  
  Woosley, RL, Annual Rev. Pharmacology & Toxicology, 1/1/2013
• It is important research, but why is it necessary?  
  Woosley, RL, Clin Pharmacol Ther, 1/1/2013
• Regulatory and Reimbursement Innovation  
  Lindor, RA, Allocco, SJ, Cheatham L, Cortese, DA, Hall RF, Mangold, WJ, Pizziconi, Poste G, Quinn B, Roth M, Saks MJ, Wassman ER, Woosley RL, Marchant GE, Sci Transl Med, 1/1/2013
• Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics  
  Postema PG, Neville J, de Jong JS, Romero K, Wilde AA, Woosley RL, Europace, 1/1/2013
• Is it possible for FDA regulatory scientists and industry scientists to work together?  
  Woosley, RL, Pharmacol Ther, 1/1/2012
• An accelerated pathway for targeted cancer therapies  
  McClellan M, Benner J, Schilsky R, Epstein D, Woosley R, Friend S, Sidransky D, Geoghegan C, Kessler D, Nat Rev Drug Discov, 1/1/2011
• Community pharmacy and pharmacist staff call center: assessment of medication safety and effectiveness  
  Higgins L, Brown M, Murphy JE, Malone DC, Armstrong, EP, Woosley RL, J Am Pharm Assoc, 1/1/2011
• The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science  
  Woosley, RL, Myers, RT, Goodsaid, F, Clin Pharmacol Ther, 1/1/2010
• New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades  
  Spigelman M, Woosley R, Gheuens J, Int J Tuberculous Lung Dis, 1/1/2010
• Research at the interface of industry, academia and regulatory science  
  Mattes WB, Walker EG, Abadie E, Sistare FD, Vonderscher J, Woodcock J, Woosley RL, Nat Biotechnol, 1/1/2010
• Time to replace Bazett's QT-correction  
  Woosley, RL, Romero, K, J Clin Pharmacol, 1/1/2009
• Warfarin Interactions Listed in Drug Information Compendia and the FDA Approved Label for Warfarin Sodium  
  Anthony M, Romero K, Malone D, Hines L, Higgins L, Woosley RL, Clinical Pharmacology & Therapeutics, 1/1/2009
• The Coalition Against major Diseases: Developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases  
  Romero K, de Mars M, Frank D, Anthony M, Neville J, Kirby L, Smith K, Woosley RL, Clinical Pharmacology & Therapeutics, 1/1/2009
• The FDA Critical Path Initiative and Its Influence on New Drug Development  
  Woodcock J, and Woosley RL, Ann Rev Med, 1/1/2008
• he translational path includes the FDA's critical path  
  Woosley RL, J Cardiovasc Transl Res, 1/1/2008
• An audience with Ray Woosley  
  Woosley R, Nat Rev Drug Discov, 1/1/2008
• Join now to see all

Books/Book Chapters

• Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease 
  Chapter: Clinical Pharmacology of Antiarrhythmic Drugs 
  Page 433 - 446Woosley RL, Farshad ShiraziEditors: Michael M. Givertz, MD, Mark E. Josephson, James de Lemos, MD Susanne Oparil, MD, Frank M. Sacks, MD.Saunders Elsevier, Philadelphia, PAEdition 3rd,2007
• Cardiac Electrophysiology from Cell to Bedside 
  Chapter: New Antiarrhythmic Drugs 
  Page 939 - 943Woosley RLEditors: Zipes DP, Jalife J.WB Saunders Company1999
• Textbook of Cardiovascular Medicine 
  Chapter: Basic Principles of Cardiovascular Clinical Pharmacology. 
  Page 989 - 1005Woosley RLEditors: Topol EJ.Lippincott-Raven Publishers, Philadelphia, PA1998
• Hurst's The Heart 
  Chapter: Antiarrhythmic Drugs 
  Page 969 - 994Woosley RLEditors: Alexander RW, Schlant RC, Fuster V.McGraw-Hill, New York, NYEdition 9th,1998
• Sudden Cardiac Death: Past, Present, and Future 
  Chapter: Drug and metabolic factors in sudden death. 
  Page 75 - 84Drici MD, Flockhart DA and Woosley RLEditors: Dunbar SB, Ellenbogen KA and Epstein AE.Futura Publishing Company, Inc.1997
• In Paediatric Cardiac Arrhythmias 
  Chapter: Pharmacology of antiarrhythmic drugs. 
  Page 260 - 278Beder SD and Woosley RLEditors: Wren C. and Campbell RWF.Oxford University Press, New York, NY1996
• The Heart Companion Handbook 
  Chapter: Assessment and management of arrhythmias 
  Page 32 - 45Woosley RLEditors: Schlant RC and Alexander RW.McGraw-Hill, Inc., New York, NYEdition 8th,1995
• Coronary Care 
  Chapter: Treatment of ventricular arrhythmias in acute myocardial infarction. 
  Page 193 - 215Woosley RL and Barbey JTEditors: Francis GS and Alpert JS.Little, Brown and Company, Boston, MAEdition 2nd,1995
• The Heart 
  Chapter: Antiarrhythmic drugs 
  Page 775 - 805Woosley RLEditors: Schlant RC, Alexander RW, O'Rourke RA, Roberts R and Sonnenblick EH.McGraw-Hill, New York, NYEdition 8th,1994
• Electropharmacological Control of Cardiac Arrhythmias: To Delay Conduction or to Prolong Refractoriness? 
  Chapter: Significance of the cardiac arrhythmia suppression trial (CAST) in the survivors of acute myocardia infarction. 
  Page 379 - 385Woosley RLEditors: Singh BN, Wellens HJJ and Hiraoka M.Futura Publishing Co., Mt. Kisco, NY1994
• Cardiovascular Pharmacology and Therapeutics 
  Chapter: Significance of pharmacokinetic principles 
  Page 15 - 29Schwartz SL, Wellstein A and Woosley RLEditors: Singh BN, Dzau VJ, Vanhoutte PM and Woosley RL.Churchill Livingstone, New York, NY1994
• Cardiovascular Pharmacology and Therapeutics 
  Chapter: Pharmacologic therapy in cardiac arrhythmias: Principles and background considerations 
  Page 595 - 616Franz MR, Koller B and Woosley RLEditors: Singh BN, Dzau VJ, Vanhoutte PM and Woosley RL.Churchill Livingstone, New York, NY1994
• Sudden Cardiac Death: Prevalence, Mechanisms, and Approaches to Diagnosis and Management 
  Chapter: Results of the Cardiac Arrhythmia Suppression Trial 
  Page 439 - 449Woosley RLEditors: Akhtar M, Myerburg RJ and Ruskin JN.Williams & Wilkins, Philadelphia, PA1994
• Antiarrhythmic Therapy: A Pathophysiologic Approach 
  Chapter: The Sicilian Gambit Approach to Antiarrhythmic Drug Actions 
  Page 85 - 101Woosley RL and Roden DMEditors: Members of the Sicilian Gambit.Futura Publishing Co., Inc., Armonk, NY1994
• Cardiac Electrophysiology: From Cell to Bedside 
  Chapter: New antiarrhythmic drugs 
  Page 1345 - 1347Woosley RLEditors: Zipes DP and Jalife J.W.B. Saunders Company, Philadelphia, PAEdition 2nd,1994
• Integration of Pharmacodynamics, and Toxicokinetics in Rational Drug Development 
  Chapter: The integration of pharmacodynamics and pharmacokinetics in rational drug development. 
  Page 225 - 238Yasuda SU, Schwartz SL, Wellstein A and Woosley RLEditors: Yacobi A, Shah VP, Skelly JP and Benet LZ.Plenum Press, New York, NY1993
• Cardiology 
  Chapter: Basic principles of clinical pharmacology 
  Sale M and Woosley RLEditors: Parmley WW and Chatterjee K.Lippincott, Philadelphia, PAEdition 2nd,1993
• The In Vivo Study of Drug Action: Principles and Application of Kinetic-Dynamic Modelling 
  Chapter: Antiarrhythmic drugs and cardiac glycosides 
  Page 277 - 301Wellstein A, Woosley RL and Schwartz SLEditors: Van Boxtel CJ, Holford NHG and Danhof M.Elsevier Science Publishers B.V., Amsterdam, Netherlands1992
• Cardiac Pacing and Electrophysiology 
  Chapter: Current Antiarrhythmic Agents: Clinical Pharmacology 
  Page 409 - 435Funck-Brentano C and Woosley R.L.Editors: El-Sherif N and Samet P.W.B. Saunders Company, Philadelphia, PAEdition 3rd,1991
• Current Management of Arrhythmias 
  Chapter: Mexiletine 
  Page 340 - 342Woosley RLEditors: Horowitz LN.BC Decker Inc., Philadelphia, PA1991
• Cardiology: an Illustrated Text/Reference 
  Chapter: Basic Principles of Clinical Pharmacology 
  Page 2.200 - 2.180Woosley RL and Roden DMEditors: Chatterjee K and Parmley WW.Gower Medical Publishing, New York, NY1991
• The Heart 
  Chapter: Antiarrhythmic Agents 
  Page 1682 - 1171Woosley RLEditors: Hurst JW, Schlant RC, Rackley CE, Sonnenblick EH, Wenger NK.McGraw-Hill, New York, NYEdition 7th,1990
• The Heart Companion Handbook 
  Chapter: Drugs Used To Treat Cardiac Arrhythmias 
  Page 288 - 297Woosley RLEditors: Schlant RC, Hurst JW.McGraw-Hill, Inc., New York, NYEdition 7th,1990
• Modern Coronary Care 
  Chapter: Treatment of Ventricular Arrhythmias in Acute Myocardial Infarction 
  Page 195 - 219Woosley RL and Roden DMEditors: Francis GS and Alpert JS.Little Brown, Boston, MA1990
• Cardiac Electrophysiology: From Cell to Bedside 
  Chapter: Antiarrhythmic Agents: Pharmacokinetics and Pharmacodynamics 
  Page 872 - 882Woosley RLEditors: Zipes DP and Jalife J.W.B. Saunders Company, Philadelphia, PA1990
• Join now to see all

Lectures

• A Symposium: Update on Allergic Disorders for the Internist 
  Washington, DC - 1/1/1993

Other

• Domperidone Is Commonly Prescribed With QT-Interacting Drugs: Review of a Community-Based Practice and a Postmarketing Adverse Drug Event Reporting Database. 
  Woosley R, PracticeUpdate
  http://www.practiceupdate.com/content/domperidone-is-commonly-prescribed-with-other-qt-interacting-drugs/48259/65/2/1
  1/7/2017
• Higher QT Interval After Energy Drink Consumption Vs. Caffeine. 
  Woosley R, PracticeUpdate
  http://www.practiceupdate.com/C/52560/56?elsca1=emc_enews_topic-alert
  1/4/2017
• Macrolide Antibiotics and the Risk of Ventricular Arrhythmia in Older Adults 
  Woosley R, PracticeUpdate
  http://www.practiceupdate.com/content/macrolide-antibiotics-and-ventricular-arrhythmia-in-older-adults/35920/65/2/1
  1/27/2016
• Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation 
  Woosley R, PracticeUpdate
  http://www.practiceupdate.com/content/coupling-data-mining-and-laboratory-experiments-to-discover-drug-interactions-causing-qt-prolongation/45065/65/2/1
  1/26/2016
• Potent Inhibition of hERG Channels by the Over-the-Counter Antidiarrheal Agent Loperamide 
  Woosley R, PracticeUpdate
  http://www.practiceupdate.com/content/causal-association-suggested-between-loperamide-and-torsades-de-pointes/44177/65/2/1
  1/7/2016
• Drugs that prolong the QT interval 
  Woosley RL and Romero K, Medscape.com
  1/17/2009
• Co-development of Diagnostics and Therapeutics, Issue Brief 
  Hayes D, Gutman S, Frank R, Roach N, Simon R and Woosley R, Conf. on Clinical Cancer Research, Brookings Institution
  1/1/2008
• Not enough know-how to save lives. 
  Woosley RL, Flockhart DA, Peck C, The Washington Post
  1/1/1998
• Pharmacokinetics and Drug Interactions in the Elderly and special Issues in Elderly African-American Populations: Workshop Summary. 
  Committee on Pharmacokinetics and Drug Interactions in the Elderly, National Academy Press
  Washington, DC - 1/1/1997
• Don't keep doctors in the dark. 
  Woosley RA and Flockhart DA, The Washington Post
  1/1/1996
• Reduce the risks in prescription drugs. 
  Woosley RL and Flockhart DA, USA Today
  1/1/1994
• Current Diagnostic and Treatment Strategies for Ventricular Arrhythmias 
  Prystowsky EN and Woosley RL, Monograph, Advanced Therapeutics Communications International
  Secaucus, NJ - 1/1/1988
• Current Concepts in the Management of Ventricular Arrhythmias 
  Prystowsky EN and Woosley RL, Monograph, Biomedical Information Corporation
  New York, NY - 1/1/1986
• Therapeutic use of dofetilide 
  Woosley RL
  http://www.uptodate.com/contents/therapeutic-use-of-dofetilide
  UpToDate, Wolters Kluwer Health - 2013-01-09
• Join now to see all